News

Organization Updates May 2019

PCI is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth. The senior positions include newly created and expanded roles in Strategic Marketing, Program Management, Clinical Services and Global Clinical Quality. Commenting on the changes, Chief Executive Officer Salim Haffar said: “The strategic direction PCI is taking […]

Phase I Clinical Trials in Australia: East Coast, US Seminars

PCI will showcase our expertise in Phase I Clinical Trials in Australia with a series of East Coast, US seminars in June 2019. June 11, Cambridge, MA (Royal Sonesta Hotel, 4pm-9pm) June 12, Bridgewater, NJ (Bridgewater Marriott, 4pm-9pm) June 13, Cary, NC (Embassy Suites by Hilton Raleigh Durham Research Triangle, 4pm-9pm) Over the last 20 […]

Rich Nelson to Demonstrate Experience in the Global Movement of Scheduled Drug Product

This year’s Clinical Trial Supply West Coast Conference will see PCI showcasing our specialist clinical trials expertise in relation to scheduled drug products. May 14-15, Burlingame, CA (Hilton San Francisco Airport Bayfront) Focusing on ‘Scheduled Drug Product – Processes and Complications in Global Logistics’, PCI’s Rich Nelson, Senior Manager, Global Logistics for Clinical Services, will […]

PCI Brexit Communication, 12th April 2019

The European Council and the UK Prime Minister have agreed and announced an extension to Article 50 with a flexible Brexit delay until 31st October 2019, with a review at the end of June. However, the UK will be able to leave the EU before this October date should a deal be agreed by UK […]

PCI Brexit Communication, 3rd April 2019

On the 29th March 2019, a vote took place on the proposed first stage of the renegotiated Brexit deal by the United Kingdom (UK) Parliament. The plan was subsequently rejected and as a result, the extended deadline agreed during the EU Summit on the 21st March 2019 for the UK to leave the European Union […]

Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity and boost powder handling capability We are pleased to announce further investment to expand our flagship manufacturing center in Tredegar, Wales. The investment at Tredegar will double our highly potent tableting capacity and see an […]

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients